Search

Your search keyword '"Abe, Kazumichi"' showing total 481 results
Start Over Author "Abe, Kazumichi"
481 results on '"Abe, Kazumichi"'

5. A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage

Author

Ninomiya, Masashi, Tsuruoka, Mio, Inoue, Jun, Hiraoka, Atsushi, Iwata, Tomoaki, Sano, Akitoshi, Sato, Kosuke, Onuki, Masazumi, Sawahashi, Satoko, Kuroda, Hidekatsu, Oikawa, Takayoshi, Fujita, Masashi, Abe, Kazumichi, Katsumi, Tomohiro, Sato, Wataru, Igarashi, Go, Iino, Chikara, Endo, Tetsu, Tanabe, Nobukazu, Numao, Hiroshi, Iijima, Katsunori, Matsumoto, Takayuki, Ohira, Hiromasa, Ueno, Yoshiyuki, and Masamune, Atsushi

Published
2023
Full Text
View/download PDF

7. APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis

Author

You, Hong, Ma, Xiong, Efe, Cumali, Wang, Guiqiang, Jeong, Sook-Hyang, Abe, Kazumichi, Duan, Weijia, Chen, Sha, Kong, Yuanyuan, Zhang, Dong, Wei, Lai, Wang, Fu-Sheng, Lin, Han-Chieh, Yang, Jin Mo, Tanwandee, Tawesak, Gani, Rino A., Payawal, Diana A., Sharma, Barjesh C., Hou, Jinlin, Yokosuka, Osamu, Dokmeci, A. Kadir, Crawford, Darrell, Kao, Jia-Horng, Piratvisuth, Teerha, Suh, Dong Jin, Lesmana, Laurentius A., Sollano, Jose, Lau, George, Sarin, Shiv K., Omata, Masao, Tanaka, Atsushi, and Jia, Jidong

Published
2022
Full Text
View/download PDF

8. Influence of skeletal muscle volume loss during lenvatinib treatment on prognosis in unresectable hepatocellular carcinoma: a multicenter study in Tohoku, Japan

Author

Fujita, Masashi, Abe, Kazumichi, Kuroda, Hidekatsu, Oikawa, Takayoshi, Ninomiya, Masashi, Masamune, Atsushi, Okumoto, Kazuo, Katsumi, Tomohiro, Sato, Wataru, Iijima, Katsunori, Endo, Tetsu, Fukuda, Shinsaku, Tanabe, Nobukazu, Numao, Hiroshi, Takikawa, Yasuhiro, Ueno, Yoshiyuki, and Ohira, Hiromasa

Published
2022
Full Text
View/download PDF

9. TAFRO syndrome complicated by porto-sinusoidal vascular liver disease with portal hypertension: a case report

Author

Hayashi, Manabu, Wada, Jun, Fujita, Masashi, Asano, Tomoyuki, Matsuoka, Naoki, Fujita, Yuya, Temmoku, Jumpei, Matsumoto, Haruki, Yashio-Furuya, Makiko, Sato, Shuzo, Kobayashi, Hiroko, Watanabe, Hiroshi, Ryoichiro, Kobashi, Waragai, Yuichi, Suzuki, Erina, Kiko, Yuichiro, Abe, Kazumichi, Takahashi, Atsushi, Masuda, Tomoyuki, Hashimoto, Yuko, Migita, Kiyoshi, and Ohira, Hiromasa

Published
2021
Full Text
View/download PDF

10. Circulating myostatin levels as a prognostic biomarker in patients with acute liver failure and late‐onset hepatic failure.

Author

Hayashi, Manabu, Abe, Kazumichi, Sugaya, Tatsuro, Takahata, Yosuke, Fujita, Masashi, Takahashi, Atsushi, and Ohira, Hiromasa

Subjects
*MYOSTATIN, *PSOAS muscles, *LIVER failure, *PROGNOSTIC models, *OVERALL survival
Abstract

Aim: Myostatin is a myokine involved in muscle mass regulation. The associations between circulating myostatin levels and clinical characteristics in patients with acute liver failure (ALF) and late‐onset hepatic failure (LOHF) are unclear. Methods: In this retrospective study, 51 patients with ALF or LOHF were included. Serum myostatin was measured using an enzyme‐linked immunosorbent assay. Results: Myostatin levels were significantly lower in patients with ALF and LOHF than in controls (ALF/LOHF: 2522 pg/mL, controls: 3853 pg/mL, p = 0.003). The prevalence of low myostatin in deceased patients was significantly higher than that in spontaneous survivors and patients who underwent liver transplantation. Patients with low myostatin levels had a high incidence of complications. There was a positive correlation between the psoas muscle index and serum myostatin levels. Patients with low myostatin levels had shorter 1‐year transplant‐free survival and shorter 1‐year overall survival than patients with high myostatin levels. Low serum myostatin levels were associated with poor prognosis independent of the Japanese scoring system for ALF ≥3, King's College criteria, or model for end‐stage liver disease score >30.5. The combination of serum myostatin levels and prognostic models for ALF significantly stratified patients according to 1‐year prognosis. Conclusions: Low serum myostatin levels were associated with a low psoas muscle index, complication rate, and poor prognosis in patients with ALF and LOHF. Assessment of circulating myostatin levels may improve the prediction of outcomes in patients with ALF and LOHF. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. A low baseline serum myostatin concentration is associated with poor clinical outcome in patients with primary biliary cholangitis.

Author

Hayashi, Manabu, Abe, Kazumichi, Sugaya, Tatsuro, Takahata, Yosuke, Fujita, Masashi, Takahashi, Atsushi, and Ohira, Hiromasa

Subjects
*TREATMENT effectiveness, *MYOSTATIN, *URSODEOXYCHOLIC acid, *CHEMOKINES, *LIVER diseases, *CHOLANGITIS, *BILIARY liver cirrhosis
Abstract

Background and Aim: Primary biliary cholangitis (PBC) is an autoimmune‐mediated cholestatic liver disease that can progress to biliary cirrhosis and liver‐related death. The associations between baseline myostatin levels and clinical outcomes in PBC patients are unknown. We aimed to clarify the influence of myostatin levels on the clinical outcomes of PBC patients. Methods: A total of 119 PBC patients were analyzed in this study. Myostatin levels were measured in stored sera before ursodeoxycholic acid treatment, and their associations with the clinical features and prognosis of PBC patients were analyzed. We analyzed the correlation between serum myostatin and chemokines/cytokines. Results: Serum myostatin was significantly lower in PBC patients (2343 pg/mL) than in healthy controls (4059 pg/mL, P < 0.001). The prevalence of patients with low myostatin levels increased according to the severity of histological fibrosis. The serum myostatin concentration was negatively correlated with the IL‐6 and leucine‐rich α2 glycoprotein levels, but the chemokine concentration was not correlated with the myostatin concentration. Low myostatin in PBC patients was associated with shorter survival without liver‐related complications (hazard ratio [HR], 3.598; 95% confidence interval [CI], 1.27–10.1; P = 0.015) and shorter transplant‐free survival (HR, 3.129; 95% CI, 1.02–9.56; P = 0.045) independent of pretreatment GLOBE score. Patients with both high pretreatment GLOBE scores and low myostatin levels had poor prognoses (log–rank test: P < 0.001). Conclusions: A low serum myostatin concentration at diagnosis was associated with poor clinical outcomes. Assessment of circulating myostatin levels may improve the prediction of outcomes in patients with PBC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Guide for the Diagnosis of Immune Checkpoint Inhibitor-Induced Liver Injury

Author

Ito, Takanori, primary, Takeuchi, Yasuto, additional, Mizuno, Kazuyuki, additional, Imai, Michitaka, additional, Yoshimaru, Yoko, additional, Abe, Kazumichi, additional, Abe, Masanori, additional, Matsuura, Takanori, additional, Yokode, Masataka, additional, Shiokawa, Masahiro, additional, Kodama, Yuzo, additional, Komuta, Mina, additional, Harada, Kenichi, additional, and Tanaka, Atsushi, additional

Published
2024
Full Text
View/download PDF

22. Diagnostic guide for immune checkpoint inhibitor‐induced liver injury.

Author

Ito, Takanori, Takeuchi, Yasuto, Mizuno, Kazuyuki, Imai, Michitaka, Yoshimaru, Yoko, Abe, Kazumichi, Abe, Masanori, Matsuura, Takanori, Yokode, Masataka, Shiokawa, Masahiro, Kodama, Yuzo, Komuta, Mina, Harada, Kenichi, and Tanaka, Atsushi

Subjects
IMMUNE checkpoint inhibitors, BILE ducts, LIVER injuries, T cells, IMMUNE checkpoint proteins, CHOLANGITIS
Abstract

With the widespread use of immune checkpoint inhibitors (ICIs), liver injury (ICI‐induced liver injury) as an immune‐related adverse event has become a major concern in clinical practice. Because severe cases of liver injury require administration of corticosteroids, a comprehensive evaluation is crucial, including clinical course, blood and imaging tests, and if necessary, pathological examination through liver biopsy. As with liver injury induced by other drugs, classification of injury type by R‐value is useful in deciding treatment strategies for ICI‐induced liver injury. Histologically, the most representative feature is an acute hepatitis‐like hepatocellular injury, characterized by diffuse lobular inflammation accompanied by CD8‐positive T lymphocytes. Another condition that can cause liver injury during ICI treatment is cholangitis accompanied by non‐obstructive bile duct dilatation and bile duct wall thickening. Many cases of ICI‐induced cholangitis are classified as non‐hepatocellular injury type, and they have been reported to respond poorly to corticosteroids. It is essential that gastroenterologists/hepatologists and doctors in various departments work in cooperation to develop a system that achieves early diagnosis and appropriate treatment of ICI‐induced liver injury. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection

Author

Suda, Goki, Hasebe, Chitomi, Abe, Masami, Kurosaki, Masayuki, Itakura, Jun, Izumi, Namiki, Uchida, Yoshihito, Mochida, Satoshi, Haga, Hiroaki, Ueno, Yoshiyuki, Abe, Kazumichi, Takahashi, Atsushi, Ohira, Hiromasa, Tsukuda, Yoko, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Kobayashi, Tomoe, Inoue, Jun, Terasita, Katsumi, Ohara, Masatsugu, Kawagishi, Naoki, Izumi, Takaaki, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, Sakamoto, Naoya, and for the NORTE Study Group

Published
2019
Full Text
View/download PDF

31. Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection

Author

Suda, Goki, Kurosaki, Masayuki, Itakura, Jun, Izumi, Namiki, Uchida, Yoshihito, Mochida, Satoshi, Hasebe, Chitomi, Abe, Masami, Haga, Hiroaki, Ueno, Yoshiyuki, Masakane, Ikuto, Abe, Kazumichi, Takahashi, Atsushi, Ohira, Hiromasa, Furuya, Ken, Baba, Masaru, Yamamoto, Yoshiya, Kobayashi, Tomoe, Kawakami, Atsuhiko, Kumagai, Kenichi, Terasita, Katsumi, Ohara, Masatsugu, Kawagishi, Naoki, Umemura, Machiko, Nakai, Masato, Sho, Takuya, Natsuizaka, Mitsuteru, Morikawa, Kenichi, Ogawa, Koji, and Sakamoto, Naoya

Published
2019
Full Text
View/download PDF

33. Association between equol and non‐alcoholic fatty liver disease in Japanese women in their 50s and 60s

Author

Takahashi, Atsushi, primary, Takahata, Yosuke, additional, Kokubun, Masae, additional, Anzai, Yukio, additional, Kogure, Atsuko, additional, Ogata, Takashi, additional, Abe, Naoto, additional, Sugaya, Tatsuro, additional, Fujita, Masashi, additional, Imaizumi, Hiromichi, additional, Hayashi, Manabu, additional, Abe, Kazumichi, additional, and Ohira, Hiromasa, additional

Published
2023
Full Text
View/download PDF

38. A new model to estimate duration of survival in patients with hepatocellular carcinoma with BCLC intermediate stage

Author

Ninomiya, Masashi, primary, Tsuruoka, Mio, additional, Inoue, Jun, additional, Hiraoka, Atsushi, additional, Iwata, Tomoaki, additional, Sano, Akitoshi, additional, Sato, Kosuke, additional, Onuki, Masazumi, additional, Sawahashi, Satoko, additional, Kuroda, Hidekatsu, additional, Oikawa, Takayoshi, additional, Fujita, Masashi, additional, Abe, Kazumichi, additional, Katsumi, Tomohiro, additional, Sato, Wataru, additional, Igarashi, Go, additional, Iino, Chikara, additional, Endo, Tetsu, additional, Tanabe, Nobukazu, additional, Numao, Hiroshi, additional, Iijima, Katsunori, additional, Matsumoto, Takayuki, additional, Ohira, Hiromasa, additional, Ueno, Yoshiyuki, additional, and Masamune, Atsushi, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results